Farnesol-induced apoptosis in Candida albicans.
Farnesol, a precursor in the isoprenoid/sterol pathway, was recently identified as a quorum-sensing molecule produced by the fungal pathogen Candida albicans. Farnesol is involved in the inhibition of germination and biofilm formation by C. albicans and can be cytotoxic at certain concentrations. In addition, we have shown that farnesol can trigger apoptosis in mammalian cells via the classical apoptotic pathways. In order to elucidate the mechanism behind farnesol cytotoxicity in C. albicans, the response to farnesol was investigated, using proteomic analysis. Global protein expression profiles demonstrated significant changes in protein expression resulting from farnesol exposure. Among the downregulated proteins were those involved in metabolism, glycolysis, protein synthesis, and mitochondrial electron transport and the respiratory chain, whereas proteins involved in folding, protection against environmental and oxidative stress, actin cytoskeleton reorganization, and apoptosis were upregulated. Cellular changes that accompany apoptosis (regulated cell death) were further analyzed using fluorescent microscopy and gene expression analysis. The results indicated reactive oxygen species accumulation, mitochondrial degradation, and positive terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) in the farnesol-exposed cells concurrent with increased expression of antioxidant-encoding and drug response genes. More importantly, the results demonstrated farnesol-induced upregulation of the caspase gene MCA1 and the intracellular presence of activated caspases. In conclusion, this study demonstrated that farnesol promotes apoptosis in C. albicans through caspase activation, implying an important physiological role for farnesol in the fungal cell life cycle with important implications for adaptation and survival.
Department of Microbial Pathogenesis, Dental School, University of Maryland, Baltimore, MD 21201, USA.
Mark E
ME
Shirtliff
Bastiaan P
BP
Krom
Roelien A M
RA
Meijering
Brian M
BM
Peters
Jingsong
J
Zhu
Mark A
MA
Scheper
Megan L
ML
Harris
Mary Ann
MA
Jabra-Rizk
D017209:Apoptosis / Q000187:drug effects*; D002176:Candida albicans / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D020169:Caspases / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005204:Farnesol / Q000494:pharmacology*; D005656:Fungal Proteins / Q000032:analysis; D020730:Guanine Nucleotide Dissociation Inhibitors / Q000502:physiology; D020287:In Situ Nick-End Labeling; D008928:Mitochondria / Q000378:metabolism; D020543:Proteome; D017382:Reactive Oxygen Species / Q000378:metabolism; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors
D005656:Fungal Proteins; D020730:Guanine Nucleotide Dissociation Inhibitors; D020543:Proteome; D017382:Reactive Oxygen Species; D062947:rho-Specific Guanine Nucleotide Dissociation Inhibitors; D005204:Farnesol; D020169:Caspases